

a 2006 0139

The invention refers to medicine, in particular to oncology and may be used for precocious noninvasive determination of the endometrial cancer aggressivity.

Summary of the invention consists in that it is determined the tryptophanhydroxylase-1 messenger RNA concentration in the endometrial and myometrial tissues, and in the case when the concentration constitutes 0...15 units it is determined a major aggressivity, 16...400 units – a medium aggressivity, 400 units and more it is determined a low aggressivity of the endometrial cancer.

Claims: 1